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ABSTRACT 
Background: Low vitamin D is implicated in various chronic pain conditions with, 
however, inconclusive findings. Vitamin D might play an important role in mechanisms being 
involved in central processing of evoked pain stimuli but less so for spontaneous clinical pain. 
Objective: To examine the relation between low serum levels of 25-hydroxyvitamin 
D3 (25-OH D) and mechanical pain sensitivity. 
Design: We studied 174 patients (mean age 48 years, 53% women) with chronic pain. 
A standardized pain provocation test was applied and pain intensity was rated on a numerical 
analogue scale (0-10). The widespread pain index and symptom severity score (incl. fatigue, 
waking unrefreshed, cognitive symptoms) following the 2010 American College of 
Rheumatology preliminary diagnostic criteria for fibromyalgia were also assessed. Serum 25-
OH D levels were measured with a chemiluminescent immunoassay. 
Results: Vitamin deficiency (25-OH D <50 nmol/l) was present in 71% of chronic 
pain patients; another 21% had insufficient vitamin D (25-OH D <75 nmol/l). After 
adjustment for demographic and clinical variables, there was a mean±SEM increase in pain 
intensity of 0.61±0.25 for each 25-nmol/l decrease in 25-OH D (p=0.011). Lower 25-OH D 
levels were also related to greater symptom severity (r=-0.21, p=0.008), but not to the 
widespread pain index (p=0.83) and fibromyalgia (p=0.51). 
Conclusions: The findings suggest a role of low vitamin D levels for heightened 
central sensitivity, particularly augmented pain processing upon mechanical stimulation in 
chronic pain patients. Vitamin D seems comparably less important for self-reports of 
spontaneous chronic pain.  
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INTRODUCTION 
Low serum levels of 25-hydroxyvitamin D3 (25-OH D) have been implicated in 
various chronic pain conditions [1], including non-specific musculoskeletal pain [2], chronic 
widespread pain [3], fibromyalgia [4], low-back pain [5], headache [6], and lumbar spinal 
stenosis [7]. This is a general health concern as the average prevalence of vitamin D 
deficiency (25-OH D <50 nmol/l) or insufficiency (25-OH D of 50-75 nmol/l [8] in chronic 
pain patients is at least 50% [2, 6, 7, 9, 10]. Nonetheless, the relationship between vitamin D 
levels and pain outcomes are not straightforward. While some studies report an inverse 
relation between vitamin D deficiency and self-reports of pain intensity at different body sites 
[7, 11], others do not [12-14]. A previous study in osteoarthritis patients found low levels of 
vitamin D to be predictive of increased mechanical pain sensitivity but not of self-reported 
clinical pain [12]. Therefore, low vitamin D levels might enhance central sensitivity to 
mechanically evoked pain, a core pathophysiological mechanism of pain processing that 
involves brain regions which are distinct from those being active in spontaneous pain [15]. 
This notion is supported by a study on rodents in which a vitamin D-deficient diet caused 
mechanical muscle hypersensitivity together with increased nociceptive skeletal muscle 
innervation, even before muscle or bone pathology occurred [16]. As vitamin D has anti-
inflammatory properties [17], pro-inflammatory cytokine production in states of vitamin D 
deficiency [18] might alter central pain processing, thereby increasing mechanical pain 
sensitivity [19]. Pain suppression by the central nervous system, including top down 
inhibition of musculoskeletal pain might also become dysfunctional if vitamin D is low [20].  
The primary aim of the present study was to further examine the relationship between 
25-OH D serum levels and several measures of central hypersensitivity in a sample of patients 
with a chronic pain disorder with or without an initial biomedical cause at the beginning of 
the disease. As part of a larger project, we also assessed the preliminary diagnostic criteria for 
fibromyalgia and measurement of symptom severity, which the American College of 
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Rheumatology (ACR) found to be methodologically rigorous for making a clinical diagnosis 
of fibromyalgia without tender point examination [21]. These criteria refer to the Widespread 
Pain Index (WPI) and the scale for Symptom Severity Score (SSS) covering the previous 
week. The WPI denotes the number of areas in which a patient feels pain and the SSS refers 
to the severity of fatigue, waking unrefreshed, and cognitive symptoms plus the extent of 
additional somatic symptoms [21]. In the realm of central hypersensitivity syndromes, to 
which fibromyalgia belongs [22], subjective pain and other somatic symptoms without 
objective clinical findings are deemed clinical manifestations of central sensitization [23]. In 
fibromyalgia increased pressure pain sensitivity due to augmented central pain processing has 
been demonstrated [24]. To this extent, a secondary aim of our study was to investigate the 
association of 25-OH D levels with WPI, SSS, and a diagnosis of fibromyalgia. 
 
MATERIALS AND METHODS 
Study Participants 
Between March 2011 and April 2013, we enrolled a consecutive sample of 292 
patients, referred to our tertiary clinic for multimodal pain therapy, aged 18 and older with 
pain of at least three months duration. The main aim of the study project is to gain a better 
understanding on the role of central hypersensitivity as a pathophysiologic concept in patients 
with chronic pain not fully explained by a biomedical cause including fibromyalgia. An 
international classification of diseases (ICD)-10 diagnosis of somatoform pain disorder 
(F45.40) or chronic pain disorder with somatic and psychological factors (F45.41) was 
required for eligibility. The German version of ICD-10 introduced the F45.41 code in 2009 to 
address the relevance of psychological factors in those pain conditions with a clear 
biomedical cause at the beginning [25], whereas for the F45.40 code biomedical causes are 
irrelevant. The institutional review board approved the study protocol and all participants 
provided informed consent. 
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All patients were examined by internal medicine residents trained in Engel’s 
biopsychosocial interview technique [26] and supervised by board-certified internists and 
psychiatrists trained in pain medicine. All patients underwent biopsychosocial history taking, 
physical examination, lab work-up, and if indicated, diagnostic imaging to assure a F45.40 or 
F45.41 diagnosis. Consultant physicians from the rheumatology, anesthesiology, neurology, 
neurosurgery, and orthopedic surgery clinics were called as needed. 
For the vitamin D substudy presented here, we excluded 118 patients who had 
incomplete data for study outcomes (i.e., algometry scores, WPI, SSS, fibromyalgia), 25-OH 
D levels, and covariates. This left 174 patients with a complete data set, allowing us to 
compute full regression models. The 174 patients did not significantly differ from the 118 
excluded patients in terms of gender (p=0.66), age (p=0.71), immigrant background (p>0.05), 
pain duration (p=0.52), depression (p=0.31), and PTSD (p=0.67).  
  
Measures of Central Hypersensitivity 
Mechanical pressure pain sensitivity: To assess mechanical pain sensitivity, we used 
peg algometry that has been validated for clinical studies against an electronic pressure 
algometer in a sample of patients with somatoform/functional or orthopedic pain [27]. A 
calibrated “clothes peg” (i.e., clamping force of 10 N at an extension of 5 mm) was applied to 
the nail bed of the middle finger for 10 seconds after which patients rated pain intensity on a 
numeric scale ranging from 0 (“no pain”) to 10 (“the most intense pain imaginable”). A “10” 
was also assigned if participants could not stand the clamping force for the entire 10 seconds 
(n=6). If patients used a range between two integers to rate pain (e.g., “between 5 and 6”), the 
middle value was taken as the definite score (e.g. “5.5”). We performed algometry on both 
middle fingers to account for possible side-specific differences in pain perception [28]. The 
average of the two ratings was used for further analyses. 
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Widespread pain index: The number of areas in which a patient had pain over the last 
week was counted up to yield a WPI score ranging from 0 to 19. The following 19 locations 
are considered for the WPI score [21]: shoulder girdle left, right; hip (buttock, trochanter) left, 
right; jaw left, right; upper arm left, right; lower arm left, right; upper leg left, right; lower leg 
left, right; upper, lower back; neck; chest; abdomen. 
Symptom severity score: The level of severity over the past week of fatigue, waking 
unrefreshed, and cognitive symptoms was indicated on a Likert scale from 0 (no problem) to 
3 (severe) together with the number of somatic symptoms in general (0=no symptoms, 3=a 
great deal of symptoms). The final SSS is between 0 and 12 [21].  
Fibromyalgia: In accordance with ACR 2010 criteria we made a diagnosis of 
fibromyalgia if the WPI was at least 7 and the SSS was at least 5 or if the WPI was between 3 
and 6 and the SSS was at least 9 [21]. Comorbid somatic conditions, which can also cause 
pain, as well as mental disorders being associated with pain complaints, were not exclusion 
criteria for fibromyalgia if judged to be not the primary cause of the patients’ pain. By study 
design, all complaints had been present for at least three months.  
 
Vitamin D Levels 
Morning fasting blood samples to determine vitamin D levels were collected shortly 
after hospital referral. Vitamin D was measured as 25-OH D in serum (nmol/l) by an 
accredited laboratory with chemiluminescent immunoassay (Institute of Clinical Chemistry, 
Bern University Hospital, Switzerland).  
 
Correlates of Vitamin D and Central Hypersensitivity 
We assessed several important correlates of 25-OH D levels, as well as our primary 
(mechanical pain sensitivity) and secondary outcomes (WPI, SSS, fibromyalgia) which might 
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act as confounding variables. Potential confounders were selected a priori and based on the 
literature to be used as covariates in statistical analysis. 
Demographic factors: Age, gender, and immigrant status (mainly Eastern and 
Southern Europe) were assessed as part of history taking. Age was shown to impact pain 
sensitivity and report in several studies [29, 30]. Compared to men, women show greater 
mechanical pain sensitivity [30] and higher prevalence of fibromyalgia [31], and they also 
report more numerous and more intense bodily symptoms [32]. Vitamin D decreases with 
aging and is found to be lower in individuals with immigrant status [33], the latter also being 
associated with increased pain reports at several body sites [34]. 
Pain history: The first manifestation of spontaneous pain was asked. We also 
collected information on current prescribed categories of pain substances (yes/no), namely 
paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), tramadolol, strong opioids, 
antiepileptics, and antidepressants. All of these medications might affect pain sensitivity and 
reports [35, 36]; moreover, anticonvulsants increase the catabolism of 25-OH D [33]. The 
total count of different pain substances (range 0-6) was used for the primary statistical 
analysis. A complementary analysis used the individual categories of pain medications. The 
presence of a comorbid somatic pain condition was categorized as yes or no.  
Body mass index: We obtained height and weight to calculate the body mass index 
(BMI, kg/m2). An elevated BMI is associated with lower vitamin D levels [33] and found in 
patients with fibromyalgia [37]. 
Psychiatric comorbidity: The treating physicians made a diagnosis of a depressive 
disorder and posttraumatic stress disorder (PTSD) in accordance with the usual clinical 
classification systems (ICD-10, DSM-IV). Depressive mood has been associated with lowered 
25-OH D [38], an elevated number of somatic symptoms, including pain [39], and 
fibromyalgia [40]. PTSD is also prevalent in fibromyalgia [40] and PTSD patients report pain 
more frequently and also have altered pain sensitivity thresholds [41]. 
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Season: Relatively reduced 25-OH levels are found during the winter season [33]. To 
account for this seasonal effect on vitamin D levels, we defined the six months with the least 
(November to April) and the most (May to October) statistical sunshine hours in Switzerland 
as winter and summer seasons, respectively.  
 
Data Analysis 
Data were analyzed using PASW 18.0 statistical software package (SPSS Inc., 
Chicago, IL, USA). Two-tailed level of significance was set at p<0.05. Values for algometry 
scores and WPI were square root transformed to obtain a normal distribution. We used 
Kruskal-Wallis and Chi-square tests for group comparisons on continuous and categorical 
variables, respectively. Spearman rank correlation coefficients were calculated to estimate the 
association between two variables. We applied recently proposed cut-offs for 25-OH D levels 
to estimate the prevalence of vitamin D deficiency (<50 nmol/l), insufficiency (50-75 nmol/l) 
and sufficiency/normal levels (>75 nmol/l) in clinical settings [8]. However, instead of these 
clinical cut-offs, we used continuously scaled 25-OH D levels in linear regression analysis to 
test for a significant relationship between vitamin D and measures of central sensitivity. This 
approach is preferred in regression-type models, as it increases statistical power [42] and 
because the severity of evoked pain and spontaneous chronic pain likely increases along a 
continuum of decreased vitamin D levels. We made multivariate adjustments for totally 10 
covariates which were subsequently entered into the model in four blocks (i.e., age and 
gender in block 1; immigrant background, season, and BMI in block 2; depression and PTSD 
in block 3; pain duration, presence of a comorbid somatic pain condition, and the number of 
pain medication categories in block 4). Multivariate normality in regression models was 
assured using Cook’s distance to verify the absence of outliers. 
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RESULTS 
Patient Characteristics 
Table 1 shows the characteristics of the 174 study participants. The sample comprised 
somewhat more women than men and patients with an immigrant background than non-
immigrants. On average, pain had been present for 7.75 years (range 0.25-57) and patients 
had been prescribed 3 different categories of pain medications. The average BMI was in the 
overweight range. Almost half of the patients qualified for a diagnosis of fibromyalgia and 
about two-fifth had a comorbid somatic condition that may be painful. Three-fourth of 
patients had clinical depression and almost every sixth patient had clinical PTSD.  
With regard to 25-OH D serum levels, 71% of patients had vitamin D deficiency and 
21% had vitamin D insufficiency; only 8% had sufficient vitamin D. The unadjusted 
comparison of characteristics between patients with deficient, insufficient and sufficient 
vitamin D levels showed significant group differences for season, immigrant background, and 
pain duration (Table 1). Post-hoc comparisons revealed that patients with sufficient vitamin D 
were more often assessed during the summer season than those with vitamin D deficiency 
(p=0.009). Immigrants were more frequent than non-immigrants in patients with vitamin D 
deficiency than in those with vitamin D insufficiency (p=0.002). Patients with vitamin D 
deficiency reported shorter pain duration than those with vitamin D insufficiency (p=0.034) 
and those with sufficient vitamin D (p=0.047). Vitamin D status did not significantly 
differentiate central hypersensitivity measures. 
 
Associations Amongst Central Sensitivity Measures 
Expectedly, patients with fibromyalgia – compared to those without fibromyalgia – 
had a greater WPI (7.86±3.31 vs. 3.22±1.97, p<0.001), higher SSS (8.45±1.57 vs. 5.57±2.03, 
p<0.001) and higher algometry scores (4.16±3.05 vs. 2.68±2.33, p=0.002). Higher algometry 
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scores were also associated with greater WPI (r=0.33, p<0.001) but not with SSS (r=0.10, 
p=0.17). In addition, greater WPI was associated with greater SSS (r=0.24, p=0.001). 
 
Associations of Continuously Scaled 25-OH D Levels With Covariates 
Lower levels of 25-OH D were found in patients with an immigrant background 
compared to non-immigrants (38.5±20.8 nmol/l vs. 45.2±22.2 nmol/l; p=0.034) and during 
the winter relative to the summer season (36.9±17.9 nmol/l vs. 45.0±23.9 nmol/l, p=0.033). 
There were no significant associations between 25-OH D levels and age (p=0.61), gender 
(p=0.69), pain duration (p=0.19), depression (p=0.21), PTSD (p=0.44), comorbid somatic 
pain conditions (p=0.24), and the count of pain medication categories (p=0.31). In terms of 
individual pain medication categories, 25-OH D levels also showed no significant relation 
with the use of paracetamol (p=0.57), NSAIDs (p=0.35), tramadolol (p=0.92), strong opioids 
(p=0.36), anticonvulsants (p=0.53), and antidepressants (p=0.96).   
 
Associations of Continuously Scaled 25-OH D Levels With Central Sensitivity Measures 
Table 2 shows the results of the five linear regression models for the association of 25-
OH D levels with measures of central hypersensitivity with subsequent adjustment for four 
blocks of covariates. In the final Model 5, which adjusted for all 10 covariates, lower levels of 
vitamin D were significantly associated with higher algometry scores (p=0.011) and higher 
SSS (p=0.008), explaining 3.9% and 4.3% of the respective variances. Figure 1 shows the 
partial regression plots of these relationships. Moreover, unstandardized coefficients B 
indicated a mean±SEM increase in algometry scores of 0.607±0.253 and in SSS of 
0.528±0.197 for each 25 nmol/l decrease in the 25-OH D level. As an example, this would 
mean that the difference in 25-OH D levels between patients with 12 nmol/l and those with 94 
nmol/l and 107 nmol/l, respectively, accounts for a 2-unit difference in algometry scores and 
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SSS. In contrast, there was no significant association between 25-OH D levels and both the 
WPI (p=0.83) and a diagnosis of fibromyalgia (p=0.63). 
The size and significance of the partial correlation coefficients changed little between 
the unadjusted Model 1 and Models 2-5 for all four central sensitivity measures. As shown in 
Table 3, this also was the case after adjustment for each pain medication category separately 
in lieu of the total count of categories of pain medications. Table 3 further shows that the 
individual categories of pain medications were not significantly related to algometry scores, 
WPI, SSS, and fibromyalgia. 
In addition to 25-OH D levels, several covariates showed a significant relationship 
with measures of central sensitivity in the fully adjusted regression model (Model 5 in Table 
2). Older patients had higher algometry scores than younger ones (r=0.183, p=0.019). Patients 
with an immigrant background (r=0.182, p=0.20) and those with a greater BMI (r=0.213, 
p=0.006) had a higher WPI. Patients with a comorbid somatic pain conditions had a lower 
SSS than those without a somatic pain conditions (r=-0.214, p=0.006). Clinical depression 
was associated with a greater SSS (r=0.337, p<0.001) and fibromyalgia (r=0.219, p=0.005). 
Likewise, PTSD was also related to a greater SSS (r=0.169, p=0.030) and fibromyalgia 
(r=0.155, p=0.047).  
 
DISCUSSION 
We investigated vitamin D levels in relation to measures of central hypersensitivity, 
primarily mechanical pain sensitivity, in patients with chronic pain of whom 47% met 
preliminary diagnostic ACR criteria for fibromyalgia. The cutoffs to distinguish deficient 
from insufficient and sufficient/normal vitamin D levels are not uniformly discussed in the 
literature and, moreover, depend upon what is felt to be an adequate level for the index 
disease under study [8]. Consensus data on adequate 25-OH D levels in chronic pain patients 
are to our knowledge not available; however, it may seem reasonable to define values below 
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50 nmol/l as vitamin D deficiency and values above 75 nmol/l as normal in clinical settings 
[8]. We found that almost three-fourths of our patients were deficient in vitamin D and 
another one-fifth showed vitamin D insufficiency. In other words, less than 10% of our 
patients had normal vitamin D levels. This low prevalence of normal vitamin D levels is 
similar to other studies on chronic pain patients in primary [2] and tertiary [10] care settings. 
About 50% of the general population would be expected to have normal vitamin D levels 
[43]. Therefore, clinicians should be aware that lower than normal vitamin D levels are more 
the rule than the exception in patients with chronic pain. 
We found a significant inverse association between continuously scaled 25-OH D 
levels and mechanical pain sensitivity. This finding is in agreement with experimental animal 
work on provoked pain sensitivity [16]. Specifically, in our sample, a decrease of 100 nmol/l 
in 25-OH D corresponded to a 2-unit increase on the numeric rating scale ranging from 0 to 
10 for pressure pain intensity. This effect size has been shown to be of clear clinical relevance 
for self-reports of spontaneous chronic musculoskeletal pain [44]. Statistical adjustment for a 
range of potentially confounding variables, including individual categories of different pain 
medications, retained the significant association of low vitamin D levels with heightened 
mechanical pain sensitivity. 
We did not observe a significant association between low 25-OH D levels and both a 
diagnosis of fibromyalgia fulfilling ACR 2010 criteria and the WPI, even after adjusting for 
important confounding variables. However, the question as to whether low vitamin D 
contributes to the development of self-reported spontaneous (i.e., unprovoked) pain in humans 
is as yet unresolved [1]. One reason for the inconsistent findings could be that low vitamin D 
deficiency mainly reflects general characteristics of the local population such as low sunlight 
exposure and overweight; for instance, not all studies show lowered vitamin D levels in 
fibromyalgia patients [14]. Another explanation for the inconsistent findings regarding 
vitamin D levels in chronic pain patients might be that self-reports of spontaneous pain, 
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including a count of body areas where “it hurts”, are not specific to core pathophysiological 
processes of mechanically evoked pain. 
We found that low 25-OH D levels were significantly associated with higher scores on 
the severity scale for somatic symptoms, even when taking psychiatric comorbidity into 
account. This is important because the number of somatic symptoms irrespective of whether 
they can be medically explained or not has been shown to be positively associated with 
anxiety and depressive symptoms [45]. In agreement, we found a clinical diagnosis of 
depression and PTSD both to be associated with elevated SSS in our chronic pain patients in 
the full multivariate-adjusted model. Those patients with a presumed additional somatic pain 
condition had a lower SSS. Therefore, the more severe the SSS the greater might the 
probability be that symptom severity of chronic pain patients is an expression of their central 
hypersensitivity. Of course, such a reasoning would not preclude the possibility that somatic 
pain conditions in their own right contributed to neuroplastic changes underlying central 
hypersensitivity at some time during the course of the disease. An approximate difference in 
25-OH D levels of 100 nmol/l between patients with deficient and normal vitamin D levels 
would seem clinically relevant regarding somatic symptom severity. For instance, a 2-unit 
difference in the fatigue score would mean that over the past week, fatigue was perceived as 
either a severe, pervasive and life-disturbing problem or as a mild problem only [21].  
Central hypersensitivity to a range of sensory stimuli from both the environment and 
“milieu interieur” is a helpful concept to explain the accumulation of somatic symptoms 
without the existence of peripheral pathophysiological or structural tissue changes. Within 
such a framework, functional somatic syndromes, including fibromyalgia and chronic fatigue 
syndrome (CFS) are now understood as central sensitivity syndromes [22]. Fibromyalgia and 
CFS are highly overlapping conditions which is evident by the fact that core symptoms which 
went into the ACR 2010 criteria for fibromyalgia, namely fatigue, unrefreshing sleep, and 
cognitive impairment [21], are also part of the Fukuda criteria to define CFS [46]. Many of 
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the symptoms that count for the SSS do not only serve the diagnostic criteria of fibromyalgia, 
but also those of other central hypersensitivity syndromes [47]. The relation between low 25-
OH D and increased SSS suggests that the role of low vitamin D for central hypersensitivity 
has implications for the severity of different somatic symptoms; i.e., above and beyond pain-
related ones. Whether vitamin D supplementation is effective to alleviate spontaneously 
reported chronic pain compared with placebo is inconclusive [48]. However, future 
randomized-controlled trials should also test for effects of vitamin D supplementation on 
mechanically evoked pain intensity. 
Our study has several limitations. The cross-sectional and non-experimental design 
preclude any causal and mechanistic inferences. Theoretically, low 25-OH D levels might 
contribute to increased central hypersensitivity of different organ systems or, alternatively, 
central processes could also inhibit vitamin D metabolism top down. The ultimate goal for 
future studies is to gain a better understanding of the mechanisms involved in transduction, 
transmission, and perception of somatic symptoms, including chronic pain, in relation to 
different levels of vitamin D. We adjusted our analyses for a range of important correlates of 
vitamin D levels and central hypersensitivity measures. However, the lack of information on 
vitamin D sources from sunlight exposure, diet, and supplements might act as an important 
confound of our findings. Our study also lacked formal evaluation of malabsorption and 
proper liver function, the latter being important for the hydroxylation of biologically inert 
vitamin D coming from the skin and diet to 25-OH D [8]. Prescribed pain medications were 
frequent and not stopped before algometry. We controlled for the total number of different 
medication categories and in complementary analysis also for individual categories, including 
anticonvulsants that enhance 25-OH D catabolism and thus might have lowered vitamin D 
levels in our sample. However, the pharmacological interactions, potential impact on liver 
function, and individual effects on pain of these medications are all difficult to account for by 
statistical procedures. In the absence of a control group without chronic pain, it remains open 
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to question whether the association between low vitamin D levels and increased algometry 
scores is specific to chronic pain patients. Because pain patients often are less mobile, 
physically active, and exposed to sunlight, the association of low vitamin D levels and higher 
algometry scores might reflect an epiphenomenon without necessarily having a cause-effect 
relationship. Whether our findings can be generalized to non-white populations and chronic 
pain conditions with a clearly defined primary biomedical cause remains unclear.  
Taken together, we found in patients with chronic pain that lowered vitamin D levels 
are associated with elevated central hypersensitivity, namely increased mechanical pain 
sensitivity and severity of somatic symptoms. As the prevalence of vitamin D 
deficiency/insufficiency is high in this population, it may seem good clinical practice to 
screen for 25-OH D levels <75 nmol/l and to consider vitamin D supplementation following 
published guidelines [8, 33].  
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Table 1. Characteristics of 174 Chronic Pain Patients per Vitamin D Status 
Variable All Vitamin D status (25-OH D) P-value 
  Deficiency 
(<50 nmol/l) 
Insufficiency 
(50-75 nmol/l) 
Sufficiency 
(>75 nmol/l)  
 
 n=174 n=124 n=36 n=14  
Age (yrs) 47.9±12.4 47.0±12.1 50.3±11.7 49.2±16.0 0.238 
Female gender (%) 53.4 52.4 55.6 57.1 0.908 
Winter season (%) 48.3 53.2 44.4 14.3 0.019 
Immigrant background (%) 61.5 66.9 38.9 71.4 0.007 
Pain duration (months) 93±111 74±88 127±129 171±179 0.025 
Body mass index (kg/m2) 27.5±5.6 28.1±5.8 26.1±5.4 25.1±4.1 0.064 
Depression (%) 76.4 76.6 72.2 85.7 0.559 
PTSD (%) 14.4 12.9 19.4 14.3 0.616 
Pain medication categories 
        Paracetamol (%) 
        NSAIDs (%) 
        Tramadolol (%) 
        Strong opioids (%) 
        Anticonvulsants (%) 
        Antidepressants (%) 
3.23±1.37 
82.8 
62.1 
52.9 
33.9 
34.5 
56.9 
3.19±1.42 
85.7 
60.5 
50.8 
32.3 
35.5 
57.3 
3.39±1.32 
80.1 
63.9 
63.9 
41.7 
33.3 
55.6 
3.14±0.95 
83.1 
71.4 
42.9 
28.6 
28.6 
57.1 
0.694 
0.897 
0.703 
0.282 
0.520 
0.864 
0.983 
Comorbid somatic pain (%) 44.3 41.1 55.6 42.9 0.306 
Algometry score 3.40±2.80 3.58±2.82 3.10±2.66 2.18±2.53 0.136 
Widespread pain index 5.38±3.54 5.41±3.56 5.64±3.77 4.43±2.77 0.662 
Symptom severity score 6.98±2.31 7.25±2.23 6.44±2.22 5.93±2.84 0.071 
Fibromyalgia (%) 46.6 47.6 47.2 35.7 0.698 
 
Values are given as means±SD or percentages. P-values were calculated using Chi-square test 
or Kruskal-Wallis test for comparisons between the three groups for vitamin D status. 
25-OH D; 25-hydroxyvitamin D3; NSAIDs, nonsteroidal anti-inflammatory drugs; PTSD, 
posttraumatic stress disorder 
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Table 2. Multivariate prediction of central hypersensitivity measures by vitamin D levels 
 Algometry 
scores 
Widespread pain 
index 
Symptom 
severity score 
Fibromyalgia 
Model 1 r=-0.213 
p=0.005 
r=-0.058 
p=0.450 
r=-0.182 
p=0.017 
r=-0.047 
p=0.541 
Model 2 r=-0.226 
p=0.003 
r=-0.065 
p=0.395 
r=-0.180 
p=0.018 
r=-0.051 
p=0.509 
Model 3 r=-0.189 
p=0.014 
r=0.032 
p=0.678 
r=-0.176 
p=0.022 
r=-0.013 
p=0.864 
Model 4 r=-0.177 
p=0.022 
r=0.010 
p=0.897 
r=-0.231 
p=0.003 
r=-0.049 
p=0.528 
Model 5 r=-0.198 
p=0.011 
r=-0.017 
p=0.828 
r=-0.206 
p=0.008 
r=-0.051 
p=0.514 
 R2=0.141 
F11,162=2.42 
p=0.008 
R2=0.190 
F11,162=3.46 
p<0.008 
R2=0.259 
F11,162=5.15 
p<0.001 
R2=0.134 
F11,162=2.27 
p=0.013 
 
Values are given as covariate-adjusted correlation coefficients (r) with p-values. Significant 
partial correlation coefficients are given in bold types. Model 1: no adjustment for covariates; 
Model 2: adjustment for age and gender; Model 3: adjustment for covariates in Model 2 plus 
immigrant status, season, and body mass index; Model 4: adjustment for covariates in Model 
3 plus depression and posttraumatic stress disorder; the fully adjusted Model 5 with model 
statistics: adjusted for covariates in Model 4 plus pain duration, comorbid somatic pain 
condition, and number of pain medication categories. 
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Table 3. Effect of pain medications on the link of vitamin D with central hypersensitivity 
Medication 
category 
Algometry 
scores 
Widespread pain 
index 
Symptom 
severity score 
Fibromyalgia 
Paracetamol r vit D = -0.204 
r medi = 0.140 
r vit D = -0.015 
r medi = -0.038 
r vit D = -0.212 
r medi = 0.112 
r vit D = 0.052 
r medi = -0.037 
NSAIDs r vit D = -0.198 
r medi = 0.002 
r vit D = -0.024 
r medi = 0.083 
r vit D = -0.198 
r medi = -0.111 
r vit D = 0.053 
r medi = -0.025 
Tramadolol r vit D = -0.197 
r medi = 0.035 
r vit D = -0.013 
r medi = 0.117 
r vit D = -0.208 
r medi = -0.031 
r vit D = 0.050 
r medi = -0.061 
Strong opioids r vit D = -0.203 
r medi = -0.115 
r vit D = -0.019 
r medi = -0.091 
r vit D = -0.212 
r medi = -0.113 
r vit D = 0.055 
r medi = 0.115 
Anticonvulsants r vit D = -0.198 
r medi = 0.010 
r vit D = -0.016 
r medi = 0.044 
r vit D = -0.209 
r medi = -0.109 
r vit D = 0.051 
r medi = 0.016 
Antidepressants r vit D = -0.198 
r medi = -0.036 
r vit D = -0.016 
r medi = -0.027 
r vit D = -0.207 
r medi = -0.035 
r vit D = 0.051 
r medi = -0.021 
 
All models were fully adjusted for age, gender, immigrant status, season, body mass index, 
depression, posttraumatic stress disorder, pain duration, comorbid somatic pain condition, and 
the respective medication category. Read model output for partial correlation coefficients (r) 
as follows; e.g., upper box to the left: The “r vit D” value shows the association between 
vitamin D levels and algometry scores with paracetamol used as the medication category. The 
“r medi” value shows the association between paracetamol use and algometry scores in that 
model. Significant partial correlation coefficients are given in bold types (p<0.05).  
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Legend to Figure 1 
The partial regression plots with fit line depict the significant associations of vitamin 
D levels with middle finger algometry scores (Panel A; p=0.011) and symptom severity scale 
scores (Panel B; p=0.008) across all 174 patients. Statistical adjustment was made for age, 
gender, immigrant status, season, body mass index, depression, posttraumatic stress disorder, 
pain duration, comorbid somatic pain condition, and total count of pain medication categories. 
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Figure 1. Multivariate Association of Vitamin D Levels With Central Hypersensitivity  
 
Panel A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
